Condition
Transplant Glomerulopathy
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
300%
3 of 1 completed with results
Key Signals
3 with results33% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 4 (2)
Trial Status
Terminated2
Completed1
Active Not Recruiting1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03380377Phase 1Completed
Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant
NCT03380962Phase 1Active Not Recruiting
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
NCT02546492Phase 4TerminatedPrimary
Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar
NCT02057523Phase 4Terminated
Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients
Showing all 4 trials